Balchem
Makes specialty nutrients, food systems, animal-feed ingredients, plant chelates, and performance gases.
Something off on this page? Send us feedback.
Profile
Develops and manufactures specialty ingredients for human and animal nutrition, food and beverages, pharmaceuticals, plant nutrition, and regulated gas applications. Revenue spans three segments, with Human Nutrition and Health the largest, while formulation, encapsulation, chelation, and specialized gas packaging connect otherwise distinct markets.
Develops specialty ingredients through three segments. Human Nutrition and Health supplies choline, chelated minerals, vitamin K2, MSM, customized food-and-beverage systems, and microencapsulation solutions. Animal Nutrition and Health sells choline chloride, encapsulated nutrients, chelated minerals, and functional ingredients for production and companion animals. Specialty Products packages performance gases for sterilization, fumigation, refrigeration, and industrial uses, and supplies chelated minerals for high-value crops.
Serves customers worldwide through its own sales force, distributors, and agents, with operations both inside and outside the United States. Formulation support, application testing, nutrient-delivery technologies, and specialized reusable gas containers underpin customer relationships. Results depend on raw-material supply, manufacturing reliability, competitive choline markets, and regulated handling and permitted uses of ethylene oxide and propylene oxide.
Company facts
Key statistics
Year to date +15.9% · Average volume (30d) 179.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 3, 2026 | UBS | Reiterate | Buy | $215 | |
| Aug 3, 2026 | H.C. Wainwright | Reiterate | Buy | $189 | $215 |
| Dec 5, 2025 | Redburn Partners | Target | $162 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026Q2 FY26 | $1.27 | $1.40 | +10.2% | $268.5M | $284.0M | +5.8% | +2.97% |
| Apr 30, 2026Q1 FY26 | $1.43 | $1.25 | −12.6% | $266.5M | $270.7M | +1.6% | −0.06% |
| Feb 20, 2026Q4 FY25 | $1.29 | $1.31 | +1.6% | $259.6M | $263.6M | +1.6% | +2.56% |
| Oct 21, 2025Q3 FY25 | $1.36 | $1.35 | −0.7% | $259.6M | $267.6M | +3.1% | +0.08% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $250.5M | $255.5M | $267.6M | $263.6M | $270.7M | $284.0M | |
| Gross profit | $88.2M | $93.1M | $95.5M | $93.9M | $101.1M | $103.7M | |
| Operating income | $51.0M | $51.4M | $54.6M | $60.1M | $55.6M | $59.2M | |
| Net income | $37.1M | $38.3M | $40.3M | $39.2M | $40.3M | $44.6M | |
| Diluted EPS | $1.13 | $1.17 | $1.24 | $1.21 | $1.25 | $1.38 | |
| Gross margin | 35.2% | 36.4% | 35.7% | 35.6% | 37.3% | 36.5% | |
| Operating margin | 20.4% | 20.1% | 20.4% | 22.8% | 20.5% | 20.9% |
Fiscal years (4-quarter sums)FY21 $799.0M · FY22 $942.4M · FY23 $922.4M · FY24 $953.7M · FY25 $1.04B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $63.2M · Total debt $166.7M · Total assets $1.69B · Shareholders' equity $1.30B
Dividends
Raised for 27 straight years — most recently to $0.96 from $0.87 in Dec 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Dec 23, 2025 | Dec 23 | Jan 20 | $0.96 | raised from $0.87 |
| Dec 26, 2024 | Dec 26 | Jan 17 | $0.87 | raised from $0.79 |
| Dec 26, 2023 | Dec 27 | Jan 19 | $0.79 | raised from $0.71 |
| Dec 23, 2022 | Dec 27 | Jan 20 | $0.71 | raised from $0.64 |
| Dec 27, 2021 | Dec 28 | Jan 21 | $0.64 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 32.13M · Float 31.95M · 99.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.96M | 15.45% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 2.22M | 6.91% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.45M | 4.50% | 13F | Aug 13, 2026 |
| State Street Corp | 1.28M | 3.99% | 13F | Aug 7, 2026 |
| Geode Capital Management, LLC | 1.12M | 3.49% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 4, 2025 | Job Leonard van Gunsteren | officer: SVP and GM, Specialty Products | −6,000 | $153.29 |
| Dec 3, 2025 | David B. Fischer | director | −8,000 | $153.97 |
| Nov 11, 2025 | Martin Luther Reid | officer: SVP Chief Supply Chain Officer | −1,200 | $154.44 |
Peers
- International Flavors & Fragrances
Broad food-ingredients and health-biosciences overlap
- Archer Daniels Midland
Feed additives and food-ingredient scale pressure
- STERIS
Ethylene oxide sterilization and AST overlap
- Sotera Health
EO terminal sterilization services overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Balchem | $178.44 | −0.06% | $5.73B | 35.1 | 32.1 | 5.3 | +11.2% |
| International Flavors & Fragrances | $83.37 | −5.20% | $22.45B | 81.4 | 25.8 | 2.3 | −29.3% |
| Archer Daniels Midland | $81.68 | +0.17% | $39.30B | 22.3 | 14.1 | 0.5 | +7.1% |
| STERIS | $233.78 | +0.06% | $22.78B | 28.6 | 20.4 | 3.8 | +7.8% |
| Sotera Health | $19.27 | 0.00% | $5.50B | 33.7 | 18.7 | 4.5 | +9.2% |
| Median | 31.1 | 19.5 | 3.0 | +7.4% |